A Prospective, Multicenter, Observational Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated with Ixazomib plus Lenalidomide and Dexamethasone - A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated with Ixazomib plus Lenalidomide and Dexamethasone

Takeda Pharmaceutical Company Limited0 个研究点目标入组 300 人开始时间: 2018年2月9日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Female patients who are nursing or pregnant 2. Patients who have been treated with ixazomib 3. Patients with hypersensitivity to any of the components of IRd therapy, their analogs or excipients 4. Patients with another active malignancy, i.e. synchronous active malignancy or previous malignancy with a disease-free period of less than 5 years, except for patients with carcinoma in situ (intraepithelial carcinoma) or intramucosal carcinoma judged to be cured by topical treatment 5. Patients who are not registered with, or comply with, the guidelines of the lenalidomide management program 6. Patients who, in the judgement of the principal investigator or investigator(s), are considered to be unsuitable for enrolment into the study

发起方